Calcifediol

• CAT Number: A000893
• CAS Number: 19356-17-3
• Molecular Formula: C27H44O2
• Molecular Weight: 400.6
• Purity: ≥95%
• Target: VD/VDR
• Solubility: >13.65mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1
• InChIKey: JWUBBDSIWDLEOM-DTOXIADCSA-N
• SMILES: CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C

25-hydroxy Vitamin D3, also known Calcifediol, 25-OH Vitamin D3 or 25-hydroxy Cholecalciferol, is an intermediate in the pathway leading to the production of 1,25-dihydroxy vitamin D3, the most receptor-active form of vitamin D. Supraphysiological 25-hydroxy vitamin D3 level at admission is associated with illness severity and mortality in critically ill patients. 25-Hydroxy vitamin D3 modulates dendritic cell phenotype and function in Crohn/’s disease.

Reference

1: Navarro-Valverde C, Quesada-Gómez JM, Pérez-Cano R, Fernández-Palacín A,
Pastor-Torres LF. Effect of calcifediol treatment on cardiovascular outcomes in
patients with acute coronary syndrome and percutaneous revascularization. Med
Clin (Barc). 2018 Jan 3. pii: S0025-7753(17)30917-X. doi:
10.1016/j.medcli.2017.11.033. [Epub ahead of print] English, Spanish. PubMed
PMID: 29306481.

2: Brancatella A, Cappellani D, Vignali E, Canale D, Marcocci C. Calcifediol
Rather Than Cholecalciferol for a Patient Submitted to Malabsortive Bariatric
Surgery: A Case Report. J Endocr Soc. 2017 Jul 14;1(8):1079-1084. doi:
10.1210/js.2017-00114. eCollection 2017 Aug 1. PubMed PMID: 29264560; PubMed
Central PMCID: PMC5686642.

3: Galassi A, Bellasi A, Ciceri P, Pivari F, Conte F, Cozzolino M. Calcifediol to
treat secondary hyperparathyroidism in patients with chronic kidney disease.
Expert Rev Clin Pharmacol. 2017 Oct;10(10):1073-1084. doi:
10.1080/17512433.2017.1371011. Epub 2017 Sep 4. Review. PubMed PMID: 28846459.

4: Vaes AMM, Tieland M, de Regt MF, Wittwer J, van Loon LJC, de Groot LCPGM.
Dose-response effects of supplementation with calcifediol on serum
25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in
older adults. Clin Nutr. 2017 Mar 31. pii: S0261-5614(17)30120-6. doi:
10.1016/j.clnu.2017.03.029. [Epub ahead of print] PubMed PMID: 28433267.

5: Extended-release calcifediol (Rayaldee) for secondary hyperparathyroidism. Med
Lett Drugs Ther. 2017 Feb 27;59(1515):36-37. PubMed PMID: 28222063.

6: Iolascon G, Moretti A, de Sire A, Calafiore D, Gimigliano F. Effectiveness of
Calcifediol in Improving Muscle Function in Post-Menopausal Women: A Prospective
Cohort Study. Adv Ther. 2017 Mar;34(3):744-752. doi: 10.1007/s12325-017-0492-0.
Epub 2017 Feb 15. PubMed PMID: 28205055.

7: Shieh A, Ma C, Chun RF, Witzel S, Rafison B, Contreras HTM, Wittwer-Schegg J,
Swinkels L, Huijs T, Hewison M, Adams JS. Effects of Cholecalciferol vs
Calcifediol on Total and Free 25-Hydroxyvitamin D and Parathyroid Hormone. J Clin
Endocrinol Metab. 2017 Apr 1;102(4):1133-1140. doi: 10.1210/jc.2016-3919. PubMed
PMID: 28187226; PubMed Central PMCID: PMC5460735.

8: Castoldi A, Herr C, Niederstraßer J, Labouta HI, Melero A, Gordon S,
Schneider-Daum N, Bals R, Lehr CM. Calcifediol-loaded liposomes for local
treatment of pulmonary bacterial infections. Eur J Pharm Biopharm. 2017
Sep;118:62-67. doi: 10.1016/j.ejpb.2016.11.026. Epub 2016 Nov 22. PubMed PMID:
27888144.

9: Sprague SM, Crawford PW, Melnick JZ, Strugnell SA, Ali S, Mangoo-Karim R, Lee
S, Petkovich PM, Bishop CW. Use of Extended-Release Calcifediol to Treat
Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J
Nephrol. 2016;44(4):316-325. Epub 2016 Sep 28. PubMed PMID: 27676085.

10: Pasquali M, Tartaglione L, Rotondi S, Muci ML, Mandanici G, Farcomeni A,
Marangella M, Mazzaferro S. Calcitriol/calcifediol ratio: An indicator of vitamin
D hydroxylation efficiency? BBA Clin. 2015 Mar 14;3:251-6. doi:
10.1016/j.bbacli.2015.03.004. eCollection 2015 Jun. PubMed PMID: 26676064; PubMed
Central PMCID: PMC4661572.